Reciprocal Interaction with Neutrophils Facilitates Cutaneous Accumulation of Liposomes
Source abstract
Abstract
Liposomes are versatile drug delivery systems in clinical use for cancer and many other diseases. Unfortunately, PEGylated liposomal doxorubicin (sLip/DOX) exhibits serious dose-limiting cutaneous toxicities, which are closely related to the extravascular accumulation of sLip/DOX in the dermis. No clinical interventions have been proposed for cutaneous toxicities due to the elusive transport pathways. Herein, we showed that the reciprocal interaction between liposomes and neutrophils played pivotal roles in liposome extravasation into the dermis. Neutrophils captured liposomes via the complement receptor 3 (CD11b/CD18) recognizing the fragment of complement component C3 (iC3b) deposited on the liposomal surface. Uptake of liposomes also activated neutrophils to induce CD11b upregulation and enhanced the ability of neutrophils to migrate outside the capillaries. Furthermore, inhibition of complement activation either by CRIg-L-FH (a C3b/iC3b targeted complement inhibitor) or blocking the phosphate negative charge in mPEG-DSPE could significantly reduce liposome uptake by neutrophils and alleviate the cutaneous accumulation of liposomes. These results validated the liposome extravasation pathway mediated by neutrophils and provided potential solutions to the devastating cutaneous toxicities occurring during sLip/DOX treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Plasmonic and Surface Plasmon Research · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmacology, School of Basic Medical Sciences & Department of Pharmacy, Shanghai Pudong Hospital, Fudan University, Shanghai 200032, P. R. China
Shanghai Institute of Immunology, Shanghai Jiaotong University School of Medicine, Shanghai 200025, P. R. China
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P. R. China
School of Pharmacy & State Key Laboratory of Molecular Engineering of Polymers, Fudan University, Shanghai 201203, P. R. China
Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, West China School of Pharmacy, Sichuan University, Chengdu 610041, P. R. China
Laboratory for Biomaterials and Drug Delivery, Division of Critical Care Medicine, Children’s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, United States
Shanghai Engineering Research Center for Synthetic Immunology, Fudan University, Shanghai 200032, P. R. China
Funding
Education and Scientific Research Project of Shanghai · National Natural Science Foundation of China
References (71)
Show source-provided references
1. 10.1016/j.addr.2012.09.03710.1016/j.addr.2012.09.037 ↗
2. 10.1126/science.109583310.1126/science.1095833 ↗
3. 10.1016/j.jconrel.2012.03.02010.1016/j.jconrel.2012.03.020 ↗
4. 10.3816/CLM.2008.n.00110.3816/CLM.2008.n.001 ↗
5. 10.1200/JCO.2001.19.14.331210.1200/JCO.2001.19.14.3312 ↗
6. 10.1001/archderm.136.12.147510.1001/archderm.136.12.1475 ↗
7. 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z ↗
8. 10.2165/00003088-200342050-0000210.2165/00003088-200342050-00002 ↗
9. FDA. Doxil (Doxorubicin Hcl Liposome Injection) for Intravenous Infusion. https://www.accessdata.fda.gov/Drugsatfda_Docs/Label/2007/050718s029lbl.Pdf (accessed June 6, 2022).
10. 10.4081/oncol.2020.44210.4081/oncol.2020.442 ↗
11. 10.1021/acsnano.2c0042310.1021/acsnano.2c00423 ↗
12. 10.1021/acsnano.7b0652410.1021/acsnano.7b06524 ↗
13. 10.1002/adma.20200359810.1002/adma.202003598 ↗
14. 10.1038/nnano.2017.5410.1038/nnano.2017.54 ↗
15. 10.1189/jlb.040724710.1189/jlb.0407247 ↗
16. 10.3389/fimmu.2014.0046710.3389/fimmu.2014.00467 ↗
17. 10.1038/nm.193910.1038/nm.1939 ↗
18. 10.1073/pnas.91.22.1068010.1073/pnas.91.22.10680 ↗
19. Mollnes T. E. · Clin. Exp. Immunol. · 1988 · 73 · 484
20. Soltis R. D. · Immunology · 1979 · 36 · 37
21. 10.1016/j.yexmp.2020.10444310.1016/j.yexmp.2020.104443 ↗
22. 10.1093/glycob/cwu10110.1093/glycob/cwu101 ↗
23. 10.1111/j.1600-065X.2009.00795.x10.1111/j.1600-065X.2009.00795.x ↗
24. 10.1016/S1074-7613(00)80653-610.1016/S1074-7613(00)80653-6 ↗
25. 10.3389/fimmu.2020.60689310.3389/fimmu.2020.606893 ↗
26. 10.1111/imm.1342010.1111/imm.13420 ↗
27. 10.1038/ni.162810.1038/ni.1628 ↗
28. 10.1016/j.bbamcr.2021.11912210.1016/j.bbamcr.2021.119122 ↗
29. 10.1172/JCI11604110.1172/JCI116041 ↗
30. 10.1172/JCI11672410.1172/JCI116724 ↗
31. 10.1002/jlb.44.6.53510.1002/jlb.44.6.535 ↗
32. 10.1096/fj.14-25804610.1096/fj.14-258046 ↗
33. 10.1096/fj.06-6186fje10.1096/fj.06-6186fje ↗
34. 10.1021/acs.nanolett.1c0394610.1021/acs.nanolett.1c03946 ↗
35. 10.1038/s41467-018-05384-110.1038/s41467-018-05384-1 ↗
36. 10.1002/adma.20200616010.1002/adma.202006160 ↗
37. 10.1002/adhm.20200207110.1002/adhm.202002071 ↗
38. 10.1038/s41565-023-01444-w10.1038/s41565-023-01444-w ↗
39. 10.1038/nri.2017.2810.1038/nri.2017.28 ↗
40. 10.1021/bi00243a02110.1021/bi00243a021 ↗
41. Alberts B. · 2002
42. 10.1016/S0168-3659(00)00240-610.1016/S0168-3659(00)00240-6 ↗
43. 10.1042/bj186059110.1042/bj1860591 ↗
44. 10.1016/S0169-409X(97)00129-410.1016/S0169-409X(97)00129-4 ↗
45. 10.1016/0005-2736(94)90231-310.1016/0005-2736(94)90231-3 ↗
46. 10.1016/0005-2736(94)90038-810.1016/0005-2736(94)90038-8 ↗
47. 10.1021/acscentsci.6b0017210.1021/acscentsci.6b00172 ↗
48. 10.1039/D0SC00863J10.1039/D0SC00863J ↗
49. 10.1039/C8SC00367J10.1039/C8SC00367J ↗
50. 10.1021/acsomega.7b0123510.1021/acsomega.7b01235 ↗
51. 10.1021/acsnano.9b0384810.1021/acsnano.9b03848 ↗
52. 10.1016/j.ydbio.2015.03.01710.1016/j.ydbio.2015.03.017 ↗
53. 10.4049/jimmunol.146.12.423410.4049/jimmunol.146.12.4234 ↗
54. 10.1093/annonc/mdg37410.1093/annonc/mdg374 ↗
55. 10.1081/LPR-12000479010.1081/LPR-120004790 ↗
56. 10.1016/j.tox.2005.07.02310.1016/j.tox.2005.07.023 ↗
57. 10.1023/A:101896512122210.1023/A:1018965121222 ↗
58. 10.1016/j.jconrel.2021.11.04210.1016/j.jconrel.2021.11.042 ↗
59. 10.1038/s41565-022-01071-x10.1038/s41565-022-01071-x ↗
60. 10.3390/molecules2307170010.3390/molecules23071700 ↗
61. 10.1021/acs.analchem.6b0343710.1021/acs.analchem.6b03437 ↗
62. 10.1021/acs.analchem.6b0310910.1021/acs.analchem.6b03109 ↗
63. 10.1016/j.jconrel.2016.06.04010.1016/j.jconrel.2016.06.040 ↗
64. 10.1111/all.1479410.1111/all.14794 ↗
65. 10.1182/blood.v78.8.2089.bloodjournal788208910.1182/blood.v78.8.2089.bloodjournal7882089 ↗
66. 10.1182/blood.v76.12.2613.261310.1182/blood.v76.12.2613.2613 ↗
67. 10.1172/JCI11547310.1172/JCI115473 ↗
68. 10.1097/00001813-199801000-0000510.1097/00001813-199801000-00005 ↗
69. 10.1017/S002211201000583510.1017/S0022112010005835 ↗
70. Jain R. K. · Cancer Res. · 1988 · 48 · 2641
71. 10.1038/s41563-019-0566-210.1038/s41563-019-0566-2 ↗